Compounds > canertinib
Page last updated: 2024-09-04

canertinib and olomoucine

canertinib has been researched along with olomoucine in 1 studies

Compound Research Comparison

Studies
(canertinib)		Trials
(canertinib)		Recent Studies (post-2010)
(canertinib)		Studies
(olomoucine)		Trials
(olomoucine)		Recent Studies (post-2010) (olomoucine)
124965227024

Protein Interaction Comparison

ProteinTaxonomycanertinib (IC50)olomoucine (IC50)
Chain A, MAP KINASE P38Homo sapiens (human)27
Chain A, PROTEIN (MAP KINASE P38)Homo sapiens (human)27
Chain A, PROTEIN (MAP KINASE P38)Homo sapiens (human)27
Chain A, Protein (map Kinase P38)Homo sapiens (human)27
Chain A, Extracellular Regulated Kinase 2Rattus norvegicus (Norway rat)27
Chain A, Extracellular Regulated Kinase 2Rattus norvegicus (Norway rat)27
G2/mitotic-specific cyclin-B2Homo sapiens (human)7
G1/S-specific cyclin-E2Homo sapiens (human)7.8
Tyrosine-protein kinase LckHomo sapiens (human)7
Cyclin-dependent kinase 1Homo sapiens (human)6.7875
Cyclin-dependent kinase 4Homo sapiens (human)7
G2/mitotic-specific cyclin-B1Homo sapiens (human)7
G2/mitotic-specific cyclin-BMarthasterias glacialis (spiny starfish)5.2571
Cyclin-A2Homo sapiens (human)7.75
G1/S-specific cyclin-D1Homo sapiens (human)7
G1/S-specific cyclin-E1Homo sapiens (human)6.4436
Cyclin-dependent kinase 2Homo sapiens (human)6.5945
Mitogen-activated protein kinase 1Homo sapiens (human)7
Vascular endothelial growth factor receptor 2Homo sapiens (human)7
Cyclin-A1Homo sapiens (human)7.75
Cyclin-dependent-like kinase 5 Homo sapiens (human)4.6
Cyclin-dependent kinase 5 activator 1Homo sapiens (human)5.6667
G2/mitotic-specific cyclin-B3Homo sapiens (human)7
Cyclin-dependent kinase 1Oryzias latipes (Japanese medaka)5.2571

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bharate, SB; Raghuvanshi, R1

Other Studies

1 other study(ies) available for canertinib and olomoucine

ArticleYear
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022